3种血栓素A_2抑制剂用于不稳定型心绞痛的成本-效果分析

Cost-Effectiveness Analysis of Three Thromboxane A_2 Inhibitors Combined with Routine Therapy in Treating Unstable Angina Pectoris

目的比较3种血栓素A2(TXA2)抑制剂奥扎格雷钠(丹奥)、丙酯(宁阳欣)、阿魏酸钠(尤尼林)联合常规疗法治疗不稳定型心绞痛的成本与效果。方法随机抽取符合诊断标准的患者128例,在常规治疗基础上分别给予奥扎格雷钠80mg(每天2次静脉滴注,方案A)、丙酯180mg以及阿魏酸钠0.3g(每天1次静脉滴注,方案B和方案C),治疗14d后对疗效和成本进行分析。结果 3组心绞痛改善总有效率分别为92.50%,83.72%,82.22%,组间比较均无统计学意义(P>0.05);人均治疗总成本分别为(4384.51±405.95)元、(4428.35±360.12)元、(4148.22±267.75)元,成本-效果比分别为4740.01,5289.48,5045.27。在方案C的基础上,每获得1个单位效果,方案A和方案B所需追加的成本分别为2298.54元和18675.33元。结论奥扎格雷钠联合常规疗法治疗不稳定型心绞痛的方案相对较优。

Objective To compare the effects and costs of three thromboxane A2（TXA2） inhibitors（sodium ozagrel,propylgallate,sodium ferulate） combined with routine therapy in treating unstable angina pectoris（UAP）.Methods A total of 128 cases according with the diagnosis standard of angina pectoris were given sodium ozagrel 80 mg（group A） by intravenous drip twice daily,propylgallate 180 mg（group B） and sodium ferulate 0.3 g（group C） by intravenous drip once daily respectively.To analyze and compare the therapeutic effects and costs after 14 d treatment among the three groups.Results The effective rates of improving pectoris were 92.50%,83.72% and 82.22% respectively,without statistically significant difference among 3 therapeutic regimens（P 〉0.05）.The total costs for 3 groups were（4 384.51 ± 405.95） yuan,（4 428.35 ± 360.12） yuan and（4 148.22 ± 267.75） yuan respectively.The cost-effectiveness ratios were 4 740.01,5 289.48 and 5 045.27 respectively.On the basis of group C,the additional costs in group A and group B were 2 298.54 yuan and 18 675.33 yuan respectively for obtaining 1 unit of effect.Conclusion Group A is relatively superior to other 2 regimens in the cost-effectiveness ratio for UAP.